No Data
No Data
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Profits May Not Reveal Underlying Issues
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) robust recent earnings didn't do much to move the stock. However the statutory profit number doesn't tell the whole story, and we h
Nootai Biotech (688076) Quarterly Report Review: Revenue exceeds market expectations, independent product release drives performance growth, peptide business flexibility is high
The company released its 2024 quarterly report: in Q1 2024, the company achieved operating income of 356 million yuan (+71.02% year over year, same below), net profit of 66 million yuan (+215.65%) to mother, deducted from the mother
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
Nootech Biotech (688076): Self-selected products are growing rapidly, 2024Q1 performance growth is in line with expectations
Investment highlights: The 2024 quarterly report was released, and performance growth was in line with expectations. On the evening of April 22, the company released its 2024 quarterly report. In the first quarter, the company achieved operating income of 356 million yuan (+71.02%); achieved return
Minsheng Securities released a research report on April 23 stating that it gave Nootai Biotech (688076.SH) a recommended rating. The main reasons for the rating include: 1) independent business selection supports rapid growth in performance, and the matri
Minsheng Securities released a research report on April 23 stating that it gave Nootai Biotech (688076.SH) a recommended rating. The main reasons for the rating include: 1) independent business selection supports rapid growth in performance, and the matrix BD team accelerates the expansion of global orders; 2) the third-generation peptide production workshop was completed and put into operation to prepare for the development of more top international customers. (Mainichi Keizai Shimbun)
Nootech Biotech (688076): High growth continues to improve profitability
Guide to this report: High performance growth continues, profitability increases, CDMO, peptide APIs and formulations continue to be released, optimistic about long-term growth potential, and maintains an increase rating. Key investment points: Maintain an increase in holdings rating. 2024Q1 Revenue 3.56
No Data